Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.
Ng ZY, Bishton M, Ritchie D, Campbell R, Gilbertson M, Hill K, Ratnasingam S, Schwarer A, Manos K, Shorten S, Ng M, Nelson N, Xin L, De Mel Widanalage S, Sunny T, Purtill D, Poon M, Johnston A, Cochrane T, Lee HP, Hapgood G, Tam C, Opat S, Hawkes E, Seymour J, Cheah CY. Ng ZY, et al. Among authors: schwarer a. Hematol Oncol. 2019 Aug;37(3):253-260. doi: 10.1002/hon.2618. Epub 2019 May 24. Hematol Oncol. 2019. PMID: 30983008
Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation.
Patil S, Spencer A, Schwarer A, Avery S, Ritchie D, Opat S, Wei A, McLean C. Patil S, et al. Among authors: schwarer a. Leuk Lymphoma. 2009 Dec;50(12):1964-8. doi: 10.3109/10428190903288456. Leuk Lymphoma. 2009. PMID: 19860614
Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma.
Grigg AP, Stone J, Milner AD, Schwarer AP, Wolf M, Prince HM, Seymour J, Gill D, Ellis D, Bashford J; Australasian Leukaemia & Lymphoma Group. Grigg AP, et al. Leuk Lymphoma. 2010 Apr;51(4):641-9. doi: 10.3109/10428191003611428. Leuk Lymphoma. 2010. PMID: 20218809 Clinical Trial.
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Bradstock KF, Link E, Collins M, Di Iulio J, Lewis ID, Schwarer A, Enno A, Marlton P, Hahn U, Szer J, Cull G, Seymour JF; Australasian Leukaemia and Lymphoma Group. Bradstock KF, et al. Among authors: schwarer a. Br J Haematol. 2014 Dec;167(5):618-25. doi: 10.1111/bjh.13086. Epub 2014 Aug 21. Br J Haematol. 2014. PMID: 25142189 Free article. Clinical Trial.
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.
Bradstock KF, Link E, Di Iulio J, Szer J, Marlton P, Wei AH, Enno A, Schwarer A, Lewis ID, D'Rozario J, Coyle L, Cull G, Campbell P, Leahy MF, Hahn U, Cannell P, Tiley C, Lowenthal RM, Moore J, Cartwright K, Cunningham I, Taper J, Grigg A, Roberts AW, Benson W, Hertzberg M, Deveridge S, Rowlings P, Mills AK, Gill D, Bardy P, Campbell L, Seymour JF; Australasian Leukaemia & Lymphoma Group. Bradstock KF, et al. Among authors: schwarer a. J Clin Oncol. 2017 May 20;35(15):1678-1685. doi: 10.1200/JCO.2016.70.6374. Epub 2017 Apr 3. J Clin Oncol. 2017. PMID: 28368672 Clinical Trial.
Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome.
Opat S, Hearps AC, Thia K, Yuen A, Rogers B, Chachage M, Moore G, Shortt J, Ryland G, Blombery P, Schwarer AP, Noori T, Trapani JA, Jaworowski A, Voskoboinik I. Opat S, et al. Among authors: schwarer ap. Blood. 2018 Feb 8;131(6):699-702. doi: 10.1182/blood-2017-08-803668. Epub 2017 Dec 12. Blood. 2018. PMID: 29233820 Free article. No abstract available.
The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia.
Minson AG, Cummins K, Fox L, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A. Minson AG, et al. Among authors: schwarer a. Blood Adv. 2019 Apr 9;3(7):1084-1091. doi: 10.1182/bloodadvances.2018028035. Blood Adv. 2019. PMID: 30944100 Free PMC article.
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Thiagarajah N, Chua CC, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong CY, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei AH; Australasian Leukaemia and Lymphoma Group (ALLG). Tiong IS, et al. Among authors: schwarer a. Blood Cancer J. 2024 Mar 26;14(1):54. doi: 10.1038/s41408-024-00996-x. Blood Cancer J. 2024. PMID: 38531863 Free PMC article.
Allogeneic haemopoietic cell transplants in Australia, 1996--a multi-centre retrospective comparison of the use of peripheral blood stem cells with bone marrow.
Nivison-Smith I, Bradstock KF, Szer J, Durrant S, Dodds A, Hermann R, Schwarer AP, Gibson J, To LB, Arthur C; Australian Bone Marrow Transplant Cooperative Sutdy Group. Nivison-Smith I, et al. Among authors: schwarer ap. Bone Marrow Transplant. 2001 Jul;28(1):21-7. doi: 10.1038/sj.bmt.1703088. Bone Marrow Transplant. 2001. PMID: 11498740
Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
Mollee P, Arthur C, Hughes T, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, Seymour JF, Martin N, Shina S, Low C, Wright S, Rodwell R, Coulston J, Morton J, Blacklock H, Taylor D, Taylor KM. Mollee P, et al. Among authors: schwarer ap. Ann Oncol. 2004 Dec;15(12):1810-5. doi: 10.1093/annonc/mdh468. Ann Oncol. 2004. PMID: 15550587 Free article. Clinical Trial.
Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
Patil S, Spencer A, Schwarer A, Lewis I, Hertzberg M, Avery S, Wei A, Noutsos T, Paul E, Taouk Y, Muirhead J. Patil S, et al. Among authors: schwarer a. Bone Marrow Transplant. 2010 Jul;45(7):1154-60. doi: 10.1038/bmt.2009.322. Epub 2009 Nov 9. Bone Marrow Transplant. 2010. PMID: 19898502 Clinical Trial.
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP. Ross DM, et al. Among authors: schwarer ap. Leukemia. 2010 Oct;24(10):1719-24. doi: 10.1038/leu.2010.185. Epub 2010 Sep 2. Leukemia. 2010. PMID: 20811403
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Iland H, Bradstock K, Seymour J, Hertzberg M, Grigg A, Taylor K, Catalano J, Cannell P, Horvath N, Deveridge S, Browett P, Brighton T, Chong L, Springall F, Ayling J, Catalano A, Supple S, Collins M, Di Iulio J, Reynolds J; Australasian Leukaemia and Lymphoma Group. Iland H, et al. Haematologica. 2012 Feb;97(2):227-34. doi: 10.3324/haematol.2011.047506. Epub 2011 Oct 11. Haematologica. 2012. PMID: 21993673 Free PMC article. Clinical Trial.
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
Fong CY, Grigoriadis G, Hocking J, Coutsouvelis J, Muirhead J, Campbell P, Paul E, Walker P, Avery S, Patil S, Spencer A, Schwarer A, Wei A. Fong CY, et al. Among authors: schwarer a. Leuk Lymphoma. 2013 Feb;54(2):336-41. doi: 10.3109/10428194.2012.713479. Epub 2012 Sep 8. Leuk Lymphoma. 2013. PMID: 22812445
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Ross DM, et al. Blood. 2013 Jul 25;122(4):515-22. doi: 10.1182/blood-2013-02-483750. Epub 2013 May 23. Blood. 2013. PMID: 23704092 Free article. Clinical Trial.
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, Forsyth CJ, Taper J, Ross DM, Beresford J, Tam C, Mills AK, Grigg AP, Hughes TP; Australasian Leukaemia and Lymphoma Group. Yeung DT, et al. Among authors: schwarer ap. Blood. 2015 Feb 5;125(6):915-23. doi: 10.1182/blood-2014-07-590315. Epub 2014 Dec 17. Blood. 2015. PMID: 25519749 Free PMC article. Clinical Trial.
The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit.
Harrison SJ, Quach H, Link E, Feng H, Dean J, Copeman M, Van De Velde H, Schwarer A, Baker B, Spencer A, Catalano J, Campbell P, Augustson B, Romeril K, Prince HM. Harrison SJ, et al. Among authors: schwarer a. Am J Hematol. 2015 May;90(5):E86-91. doi: 10.1002/ajh.23967. Epub 2015 Feb 27. Am J Hematol. 2015. PMID: 25651830 Free article. Clinical Trial.
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators. Dimopoulos MA, et al. Among authors: schwarer a. Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5. Lancet Oncol. 2016. PMID: 26671818 Free article. Clinical Trial.
The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemia.
Fox LC, Cummins KD, Costello B, Yeung D, Cleary R, Forsyth C, Tatarczuch M, Burbury K, Motorna O, Shortt J, Fleming S, McQuillan A, Schwarer A, Harrup R, Holmes A, Ratnasingam S, Chan KL, Hsu WH, Ashraf A, Putt F, Grigg A. Fox LC, et al. Among authors: schwarer a. Blood Adv. 2017 May 15;1(13):802-811. doi: 10.1182/bloodadvances.2016003889. eCollection 2017 May 23. Blood Adv. 2017. PMID: 29296724 Free PMC article.
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, Schwarer AP, Branford S, Hughes TP; Australasian Leukaemia and Lymphoma Group (ALLG). Ross DM, et al. Among authors: schwarer ap. Leukemia. 2018 Dec;32(12):2572-2579. doi: 10.1038/s41375-018-0264-0. Epub 2018 Oct 12. Leukemia. 2018. PMID: 30315232
A synonymous GATA2 variant underlying familial myeloid malignancy with striking intrafamilial phenotypic variability.
Fox LC, Tan M, Brown AL, Arts P, Thompson E, Ryland GL, Lickiss J, Scott HS, Poplawski NK, Phillips K, Came NA, James P, Ting SB, Ritchie DS, Szer J, Hahn CN, Schwarer A, Blombery P. Fox LC, et al. Among authors: schwarer a. Br J Haematol. 2020 Sep;190(5):e297-e301. doi: 10.1111/bjh.16819. Epub 2020 Jun 3. Br J Haematol. 2020. PMID: 32488879 Free article. No abstract available.
Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD).
Kalff A, Khong T, Ramachandran M, Walker P, Schwarer A, Roberts AW, Campbell P, Filshie R, Norton S, Reynolds J, Young M, Pierceall W, Thakurta A, Guo M, Oppermann U, Wang M, Ren Y, Kennedy N, Parekh S, Spencer A. Kalff A, et al. Among authors: schwarer a. Leuk Lymphoma. 2021 Dec;62(12):2981-2991. doi: 10.1080/10428194.2021.1948030. Epub 2021 Jul 15. Leuk Lymphoma. 2021. PMID: 34263697 Clinical Trial.
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Branford S, Rudzki Z, Harper A, Grigg A, Taylor K, Durrant S, Arthur C, Browett P, Schwarer AP, Ma D, Seymour JF, Bradstock K, Joske D, Lynch K, Gathmann I, Hughes TP. Branford S, et al. Among authors: schwarer ap. Leukemia. 2003 Dec;17(12):2401-9. doi: 10.1038/sj.leu.2403158. Leukemia. 2003. PMID: 14523461 Clinical Trial.
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.
Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T, Gill D, Eliadis P, Joshua D, Cannell P, Schwarer AP, Durrant S, Gillett A, Koutts J, Taylor K, Bashford J, Arthur C, Enno A, Dunlop L, Szer J, Leahy M, Juneja S, Young GA; Australasian Leukaemia and Lymphoma Group. Bradstock KF, et al. Among authors: schwarer ap. Blood. 2005 Jan 15;105(2):481-8. doi: 10.1182/blood-2004-01-0326. Epub 2004 Jun 22. Blood. 2005. PMID: 15213095 Free article. Clinical Trial.
A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
Bow EJ, Rotstein C, Noskin GA, Laverdiere M, Schwarer AP, Segal BH, Seymour JF, Szer J, Sanche S. Bow EJ, et al. Among authors: schwarer ap. Clin Infect Dis. 2006 Aug 15;43(4):447-59. doi: 10.1086/505393. Epub 2006 Jul 10. Clin Infect Dis. 2006. PMID: 16838234 Clinical Trial.
Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.
Wirth A, Prince HM, Wolf M, Stone JM, Matthews J, Gibson J, Macleod C, Szer J, Grigg A, To B, Roos D, Schwarer AP, Davis S; Australasian Leukaemia and Lymphoma Group. Wirth A, et al. Among authors: schwarer ap. Bone Marrow Transplant. 2005 Feb;35(3):291-8. doi: 10.1038/sj.bmt.1704759. Bone Marrow Transplant. 2005. PMID: 15558040 Clinical Trial.
Pamidronate reduces bone loss after allogeneic stem cell transplantation.
Grigg AP, Shuttleworth P, Reynolds J, Schwarer AP, Szer J, Bradstock K, Hui C, Herrmann R, Ebeling PR. Grigg AP, et al. Among authors: schwarer ap. J Clin Endocrinol Metab. 2006 Oct;91(10):3835-43. doi: 10.1210/jc.2006-0684. Epub 2006 Jul 11. J Clin Endocrinol Metab. 2006. PMID: 16835281 Clinical Trial.
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Tiong IS, Dillon R, Ivey A, Teh TC, Nguyen P, Cummings N, Taussig DC, Latif AL, Potter NE, Runglall M, Russell NH, Raj K, Schwarer AP, Fong CY, Grigg AP, Wei AH. Tiong IS, et al. Among authors: schwarer ap. Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26. Br J Haematol. 2021. PMID: 32458446 Free PMC article.
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, Joske D, Lynch K, Hughes T. Branford S, et al. Among authors: schwarer ap. Blood. 2004 Nov 1;104(9):2926-32. doi: 10.1182/blood-2004-03-1134. Epub 2004 Jul 15. Blood. 2004. PMID: 15256429 Free article.
High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia.
Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J. Marquis M, et al. Among authors: schwarer a. Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. Blood Cancer J. 2018. PMID: 30061630 Free PMC article.
Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.
Hughes TP, Grigg A, Szer J, Ho J, Ma D, Dale BM, Green RM, Norman JE, Sage RE, Herrmann R, Cannell P, Schwarer AP, Taylor K, Atkinson K, Arthur C. Hughes TP, et al. Among authors: schwarer ap. Br J Haematol. 1997 Mar;96(3):635-40. doi: 10.1046/j.1365-2141.1997.d01-2068.x. Br J Haematol. 1997. PMID: 9054675 Free article.
A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study.
Giles FJ, Shan J, Advani SH, Akan H, Aydogdu I, Aziz Z, Azim HA, Bapsy PP, Buyukkececi F, Chaimongkol B, Chen PM, Cheong SK, Ferhanoglu B, Hamza R, Khalid HM, Intragumtornchai T, Kim SW, Kim SY, Koc H, Kumar L, Kumar R, Lei KI, Lekhakula A, Muthalib A, Patel M, Poovalingam VP, Prayoonwiwat W, Rana F, Reksodiputro AH, Ruff P, Sagar TG, Schwarer AP, Song HS, Suh CW, Suharti C, Supindiman I, Tee GY, Thamprasit T, Villalon AH, Wickham NR, Wong JE, Yalcin A, Jootar S; International Oncology Study Group NHL1 Study. Giles FJ, et al. Among authors: schwarer ap. Leuk Lymphoma. 2000 Dec;40(1-2):95-103. doi: 10.3109/10428190009054885. Leuk Lymphoma. 2000. PMID: 11426633 Clinical Trial.
Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim.
To LB, Bashford J, Durrant S, MacMillan J, Schwarer AP, Prince HM, Gibson J, Lewis I, Swart B, Marty J, Rawling T, Ashman L, Charles S, Cohen B. To LB, et al. Among authors: schwarer ap. Bone Marrow Transplant. 2003 Mar;31(5):371-8. doi: 10.1038/sj.bmt.1703860. Bone Marrow Transplant. 2003. PMID: 12634728 Clinical Trial.
Hydroxyurea-induced fever and hepatitis.
Westerman DA, Schwarer A, Grigg AP. Westerman DA, et al. Among authors: schwarer a. Aust N Z J Med. 1998 Oct;28(5):657-9. doi: 10.1111/j.1445-5994.1998.tb00664.x. Aust N Z J Med. 1998. PMID: 9847957 No abstract available.
Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Arthur C, Bashford J, Brighton T, Cannell P, Dunlop L, Durrant S, Enno A, Eliadis P, Gill D, Gillett A, Gottlieb D, Januszewicz H, Joshua D, Leahy M, Schwarer A, Taylor K; Australian Leukaemia Study Group. Bradstock K, et al. Among authors: schwarer a. Leukemia. 2001 Sep;15(9):1331-8. doi: 10.1038/sj.leu.2402218. Leukemia. 2001. PMID: 11516093 Clinical Trial.
Abnormal cervical cytology in bone marrow transplant recipients.
Sasadeusz J, Kelly H, Szer J, Schwarer AP, Mitchell H, Grigg A. Sasadeusz J, et al. Among authors: schwarer ap. Bone Marrow Transplant. 2001 Aug;28(4):393-7. doi: 10.1038/sj.bmt.1703141. Bone Marrow Transplant. 2001. PMID: 11571513
Urinary cytology in multiple myeloma.
Patil S, Schwarer A, McLean C. Patil S, et al. Among authors: schwarer a. Cytopathology. 2008 Apr;19(2):130-1. doi: 10.1111/j.1365-2303.2007.00445.x. Epub 2007 May 3. Cytopathology. 2008. PMID: 17488260 No abstract available.
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, Filshie R, Mills AK, Fay K, Durrant S, Januszewicz H, Joske D, Underhill C, Dunkley S, Lynch K, Grigg A; Australasian Leukaemia and Lymphoma Group. Hughes TP, et al. Among authors: schwarer a. Blood. 2008 Nov 15;112(10):3965-73. doi: 10.1182/blood-2008-06-161737. Epub 2008 Sep 3. Blood. 2008. PMID: 18768781 Free article. Clinical Trial.
Malignant melanoma mimicking acute leukemia.
Tran B, Fong C, Tong M, Hosking P, Schwarer AP, Parente P. Tran B, et al. J Clin Oncol. 2009 Aug 20;27(24):e62-4. doi: 10.1200/JCO.2009.21.9956. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487374 No abstract available.
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.
Tan P, Tiong IS, Fleming S, Pomilio G, Cummings N, Droogleever M, McManus J, Schwarer A, Catalano J, Patil S, Avery S, Spencer A, Wei A. Tan P, et al. Among authors: schwarer a. Oncotarget. 2016 Nov 29;8(32):52269-52280. doi: 10.18632/oncotarget.13699. eCollection 2017 Aug 8. Oncotarget. 2016. PMID: 28881728 Free PMC article.
Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years.
Marks DI, Cullis JO, Ward KN, Lacey S, Syzdlo R, Hughes TP, Schwarer AP, Lutz E, Barrett AJ, Hows JM, Batchelor JR, Goldman JM. Marks DI, et al. Among authors: schwarer ap. Ann Intern Med. 1993 Aug 1;119(3):207-14. doi: 10.7326/0003-4819-119-3-199308010-00005. Ann Intern Med. 1993. PMID: 8391772
Acute pancreatitis complicating a bone marrow harvest.
Beamish N, Schwarer AP, Watson AM, Roberts S, O'Brien P, Morgan B. Beamish N, et al. Among authors: schwarer ap. Bone Marrow Transplant. 1997 Mar;19(5):525-6. doi: 10.1038/sj.bmt.1700691. Bone Marrow Transplant. 1997. PMID: 9052925
Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen.
Dawson MA, Schwarer AP, Muirhead JL, Bailey MJ, Bollard GM, Spencer A. Dawson MA, et al. Among authors: schwarer ap. Bone Marrow Transplant. 2005 Sep;36(5):389-96. doi: 10.1038/sj.bmt.1705069. Bone Marrow Transplant. 2005. PMID: 15980882 Clinical Trial.
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up.
Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S, Aebi S, Viale G, Price KN, Goldhirsch A; International Breast Cancer Study Group. Colleoni M, et al. Ann Oncol. 2009 Aug;20(8):1344-51. doi: 10.1093/annonc/mdp024. Epub 2009 May 25. Ann Oncol. 2009. PMID: 19468030 Free PMC article. Clinical Trial.
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.
Hughes TP, Leber B, Cervantes F, Spector N, Pasquini R, Clementino NCD, Schwarer AP, Dorlhiac-Llacer PE, Mahon FX, Rea D, Guerci-Bresler A, Kamel-Reid S, Bendit I, Acharya S, Glynos T, Dalal D, Branford S, Lipton JH. Hughes TP, et al. Among authors: schwarer ap. Leukemia. 2017 Nov;31(11):2529-2531. doi: 10.1038/leu.2017.247. Epub 2017 Aug 3. Leukemia. 2017. PMID: 28862704 Free PMC article. Clinical Trial. No abstract available.
147 results